Skip Navigation

European Journal of Heart Failure 2009 11(2):111-112; doi:10.1093/eurjhf/hfn039
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Eur J Heart Fail
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fu, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fu, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Inflammation in chronic heart failure: what is familiar, what is unfamiliar?

Michael Fu*

Department of Clinical and Molecular Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden

* Corresponding author: Department of Medicine, Sahlgrenska University Hospital/Sahlgrenska, SE 413 45 Göteborg, Sweden. Tel: +46 31 342 1000, Fax: +46 31 823762, Email: Michael.fu@wlab.gu.se

This editorial refers to ‘Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology’{dagger} by Stephane Heymans et al., on page 119 and ‘Immunological mechanisms of pentoxifylline in chronic heart failure’{ddagger} by Steven Shaw et al., on page 113

The first 10% of the full text of this article appears below.


   Introduction
 
Inflammation is commonly observed in patients with chronic heart failure (CHF), and portends a worsening functional capacity and poorer prognosis. The recognition of inflammation as a common, important, and treatable condition in CHF has contributed to intensified research for an effective anti-inflammatory therapy in CHF. However, when sequential multicentre placebo-controlled studies1–5 failed to show any clinical benefit, it became uncertain whether anti-inflammatory therapy really does influence CHF outcome. We may, in fact, wonder what is . . . [Full Text of this Article]


   What is familiar?
 

   What is unfamiliar?
 

   Two comprehensive reviews in this issue
 

   Why research on inflammation should continue despite failed clinical trials?
 

   Summary
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Eur J Heart Fail:

Immunological mechanisms of pentoxifylline in chronic heart failure
Steven M. Shaw, Mohammed K.H. Shah, Simon G. Williams, and James E. Fildes
Eur J Heart Fail 2009 11: 113-118. [Abstract] [Full Text]  

Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology
Stephane Heymans, Emilio Hirsch, Stefan D. Anker, Pal Aukrust, Jean-Luc Balligand, Jan W. Cohen-Tervaert, Helmut Drexler, Gerasimos Filippatos, Stephan B. Felix, Lars Gullestad, Denise Hilfiker-Kleiner, Stefan Janssens, Roberto Latini, Gitte Neubauer, Walter J. Paulus, Burkert Pieske, Piotr Ponikowski, Blanche Schroen, Heinz-Peter Schultheiss, Carsten Tschöpe, Marc Van Bilsen, Faiez Zannad, John McMurray, and Ajay M. Shah
Eur J Heart Fail 2009 11: 119-129. [Abstract] [Full Text]